FY2025 · ended Dec 31, 2025 · Revenue $76.20M, -44.8% YoY · Filed Mar 16, 2026
CytomX Therapeutics, Inc. (CTMX) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $76.2 million and a net loss of $17.4 million. Free cash flow was -$75.8 million. As of Sep 30, 2026 it held $348.0 million in cash and investments and $4.4 million in total debt.
Revenue (TTM)
$14.03M
-87.7% vs year-ago TTM
Net income (TTM)
$-85.42M
-404.9% vs year-ago TTM
Operating cash flow (TTM)
$-50.21M
+30.5% vs year-ago TTM
Free cash flow (TTM)
$-51.00M
+29.5% vs year-ago TTM
EPS (TTM)
$-0.44
-284.4% vs year-ago TTM
Dividend per share
None
Shares outstanding
170.19M
+112.5% vs prior year
Net cash
$343.59M
as of Sep 30, 2026
Operating margin
-676.4%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CTMX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC filer status
- Accelerated filer
- SEC CIK
- 1501989
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $76.2M | $138.1M | $101.2M | $53.2M | $37.3M |
| Operating income | -$22.4M | $25.0M | -$6.5M | -$101.3M | -$116.0M |
| Net income | -$17.4M | $31.9M | -$569,000 | -$99.3M | -$115.9M |
| Operating cash flow | -$75.6M | -$86.2M | -$56.0M | -$110.8M | -$119.0M |
| Free cash flow | -$75.8M | -$86.5M | -$56.9M | -$112.5M | -$120.6M |
| Total assets | $151.6M | $120.5M | $201.8M | $260.9M | $339.4M |
| Total liabilities | $52.6M | $121.0M | $249.2M | $346.6M | $339.9M |
| Stockholders' equity | $99.0M | -$456,000 | -$47.4M | -$85.8M | -$459,000 |
| Cash and investments | $137.1M | $100.6M | $174.5M | $193.7M | $305.2M |
| Total debt | $4.2M | $9.4M | $14.0M | $18.1M | $21.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Officer or director change
|
Jul 27, 2026 | Jul 24, 2026 |
| 8-K |
Current report
Officer or director change, Bylaw or fiscal year change, Shareholder vote results
|
Jun 22, 2026 | Jun 17, 2026 |
All 800 CytomX Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.